Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events.
Chng
Wee J
WJ
Mulligan
George
G
Bryant
Barbara
B
Bergsagel
Leif
L
D000970:Antineoplastic Agents / Q000008:administration & dosage; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000401:mortality*; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics*; D011003:Ploidies; D011719:Pyrazines / Q000008:administration & dosage; D012008:Recurrence; D015996:Survival Rate
D000970:Antineoplastic Agents; D001897:Boronic Acids; D009363:Neoplasm Proteins; D011719:Pyrazines; D000069286:Bortezomib